Literature DB >> 23465280

Expression of the oncofetal protein IGF2BP3 in endometrial clear cell carcinoma: assessment of frequency and significance.

Oluwole Fadare1, Sharon X Liang, Marta A Crispens, Howard W Jones, Dineo Khabele, Katja Gwin, Wenxin Zheng, Khaled Mohammed, Vinita Parkash, Jonathan L Hecht, Mohamed M Desouki.   

Abstract

Insulin-like growth factor-II messenger RNA-binding protein 3 (IGF2BP3 or IMP3) is a biomarker whose expression has been found to be a negative prognostic factor in several neoplasms including ovarian clear cell carcinoma (CCC). In this study, we analyzed the frequency and clinicopathologic significance of IMP3 expression, as assessed by immunohistochemistry and as scored using a modified H-score system, in a cohort of 50 endometrial CCCs. Cases with scores of 0 to 100, 101 to 200, and 201 to 300 were classified as negative/mildly positive (n = 17), moderately positive (n = 20), and strongly positive (n = 13), respectively. A distinctive pattern of increased staining at the myoinvasive front (relative to the main tumor) was evident in 46% of the cases with evaluable foci of myometrial invasion. Moderate/strong IMP3 staining was associated with a tumor architectural pattern that has been reported to be of poor prognostic significance: at least 10% of the tumor composed of solid architecture or individual infiltrating tumor cells (P = .01). Increasing levels of IMP3 expression showed a trend toward decreasing relapse-free survival (RFS; median survival, 75.6, 81.3, and 48.4 months for the negative/mildly, moderately, and strongly positive groups, respectively [P = .09]). However, IMP3 expression was not significantly associated with reduced overall survival or RFS in a multivariate analytic model. The finding in a subset of our cases of increased IMP3 expression at the tumoral myoinvasive front is consistent with a role for IMP3 in invasiveness, as is the trend toward reduced RFS in cases expressing IMP3 at high levels. These preliminary findings suggest that IMP3 expression may be involved in the pathogenesis of CCC and is worthy of further exploration.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Clear cell carcinoma; Endometrium; IMP3; Insulin-like growth factor-II mRNA-binding protein

Mesh:

Substances:

Year:  2013        PMID: 23465280      PMCID: PMC3888088          DOI: 10.1016/j.humpath.2012.12.003

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  29 in total

1.  Pathologic quiz case: a 70-year-old woman with postmenopausal bleeding. Endometrial intraepithelial carcinoma, clear cell type.

Authors:  Farah Moid; Katherine Berezowski
Journal:  Arch Pathol Lab Med       Date:  2004-11       Impact factor: 5.534

2.  Expression of the insulin-like growth factor-II mRNA-binding protein 3 (IMP3) and carcinoembryonic antigen (CEA) in mucinous minimal deviation adenocarcinoma.

Authors:  Ying He; Lei Li; Wei Jiang; Dan-qing Wang; Lian Xu; Qin Huang; Yan Zhang; Kai-xuan Yang
Journal:  Pathol Res Pract       Date:  2011-04-16       Impact factor: 3.250

3.  IMP3 distinguishes uterine serous carcinoma from endometrial endometrioid adenocarcinoma.

Authors:  Paulette Mhawech-Fauceglia; Francois R Herrmann; Har Rai; Nana Tchabo; Shashikant Lele; Iyare Izevbaye; Kunle Odunsi; Richard T Cheney
Journal:  Am J Clin Pathol       Date:  2010-06       Impact factor: 2.493

4.  RNA-binding protein insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor invasion and predicts early recurrence and poor prognosis in hepatocellular carcinoma.

Authors:  Yung-Ming Jeng; Cheng-Chi Chang; Fu-Chang Hu; Han-Yi E Chou; Hsin-Lien Kao; Ting-Huang Wang; Hey-Chi Hsu
Journal:  Hepatology       Date:  2008-10       Impact factor: 17.425

Review 5.  A family of IGF-II mRNA binding proteins (IMP) involved in RNA trafficking.

Authors:  F C Nielsen; J Nielsen; J Christiansen
Journal:  Scand J Clin Lab Invest Suppl       Date:  2001

6.  Clear cell carcinoma of the ovary: a study of 59 cases.

Authors:  M A Crozier; L J Copeland; E G Silva; D M Gershenson; C A Stringer
Journal:  Gynecol Oncol       Date:  1989-11       Impact factor: 5.482

7.  Morphologic and other clinicopathologic features of endometrial clear cell carcinoma: a comprehensive analysis of 50 rigorously classified cases.

Authors:  Oluwole Fadare; Wenxin Zheng; Marta A Crispens; Howard W Iii Jones; Dineo Khabele; Katja Gwin; Sharon X Liang; Khaled Mohammed; Mohamed M Desouki; Vinita Parkash; Jonathan L Hecht
Journal:  Am J Cancer Res       Date:  2013-01-18       Impact factor: 6.166

8.  The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.

Authors:  Wenxin Zheng; Xiaofang Yi; Oluwole Fadare; Sharon X Liang; Maritza Martel; Peter E Schwartz; Zhong Jiang
Journal:  Am J Surg Pathol       Date:  2008-02       Impact factor: 6.394

9.  Insulin growth factor-2 binding protein 3 (IGF2BP3) is a glioblastoma-specific marker that activates phosphatidylinositol 3-kinase/mitogen-activated protein kinase (PI3K/MAPK) pathways by modulating IGF-2.

Authors:  Ramaswamy Suvasini; Bhargava Shruti; Balaram Thota; Sridevi Vijay Shinde; Dinorah Friedmann-Morvinski; Zahid Nawaz; Krishnarao Venkatesh Prasanna; Kandavel Thennarasu; Alangar Sathyaranjandas Hegde; Arimappamagan Arivazhagan; Bangalore Ashwathnarayanarao Chandramouli; Vani Santosh; Kumaravel Somasundaram
Journal:  J Biol Chem       Date:  2011-05-25       Impact factor: 5.157

10.  Regulation of IMP3 by EGFR signaling and repression by ERβ: implications for triple-negative breast cancer.

Authors:  S Samanta; V M Sharma; A Khan; A M Mercurio
Journal:  Oncogene       Date:  2012-01-23       Impact factor: 9.867

View more
  10 in total

1.  IGF2BP3 enhances the mRNA stability of E2F3 by interacting with LINC00958 to promote endometrial carcinoma progression.

Authors:  Cuicui Wang; Fanfei Kong; Jian Ma; Jianing Miao; Peng Su; Hui Yang; Qing Li; Xiaoxin Ma
Journal:  Cell Death Discov       Date:  2022-06-08

2.  RNA-binding protein IGF2BP3 targeting of oncogenic transcripts promotes hematopoietic progenitor proliferation.

Authors:  Jayanth Kumar Palanichamy; Tiffany M Tran; Jonathan M Howard; Jorge R Contreras; Thilini R Fernando; Timothy Sterne-Weiler; Sol Katzman; Masoud Toloue; Weihong Yan; Giuseppe Basso; Martina Pigazzi; Jeremy R Sanford; Dinesh S Rao
Journal:  J Clin Invest       Date:  2016-03-14       Impact factor: 14.808

3.  Prognostic value of the IASLC/ATS/ERS classification and IMP3 expression in lung adenocarcinoma of Chinese cases.

Authors:  Xiangjie Sun; Ping Wei; Chen Shen; Yusi Yang; Yiqin Wang; Yuan Li; Xiang Du
Journal:  Am J Cancer Res       Date:  2015-06-15       Impact factor: 6.166

4.  Development and validation of m6A regulators' prognostic significance for endometrial cancer.

Authors:  Xuecheng Pang; Xiang Zhang; Yue Huang; Sumin Qian
Journal:  Medicine (Baltimore)       Date:  2021-07-02       Impact factor: 1.817

5.  The Discovery of Novel Biomarkers Improves Breast Cancer Intrinsic Subtype Prediction and Reconciles the Labels in the METABRIC Data Set.

Authors:  Heloisa Helena Milioli; Renato Vimieiro; Carlos Riveros; Inna Tishchenko; Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2015-07-01       Impact factor: 3.240

6.  Insulin-Like Growth Factor II mRNA-Binding Protein 3 (IMP3) as a Useful Immunohistochemical Marker for the Diagnosis of Adenocarcinoma of Small Intestine.

Authors:  Seiichi Daikuhara; Takeshi Uehara; Kayoko Higuchi; Noriko Hosaka; Mai Iwaya; Yasuhiro Maruyama; Kazuyuki Matsuda; Norikazu Arakura; Eiji Tanaka; Hiroyoshi Ota
Journal:  Acta Histochem Cytochem       Date:  2015-12-18       Impact factor: 1.938

Review 7.  Translational Dysregulation in Cancer: Molecular Insights and Potential Clinical Applications in Biomarker Development.

Authors:  Christos Vaklavas; Scott W Blume; William E Grizzle
Journal:  Front Oncol       Date:  2017-07-26       Impact factor: 6.244

8.  Clear cell carcinomas of the ovary: a mono-institutional study of 73 cases in China with an analysis of the prognostic significance of clinicopathological parameters and IMP3 expression.

Authors:  Rui Bi; Xuxia Shen; Weiwei Zhang; Yufan Cheng; Zheng Feng; Xu Cai; Wentao Yang
Journal:  Diagn Pathol       Date:  2016-02-02       Impact factor: 2.644

9.  RNA-binding protein IMP3 is a novel regulator of MEK1/ERK signaling pathway in the progression of colorectal Cancer through the stabilization of MEKK1 mRNA.

Authors:  Meng Zhang; Senlin Zhao; Cong Tan; Yanzi Gu; Xuefeng He; Xiang Du; Dawei Li; Ping Wei
Journal:  J Exp Clin Cancer Res       Date:  2021-06-21

10.  CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes.

Authors:  Shariska Petersen; Andrew J Wilson; Jeff Hirst; Katherine F Roby; Oluwole Fadare; Marta A Crispens; Alicia Beeghly-Fadiel; Dineo Khabele
Journal:  Gynecol Oncol       Date:  2020-02-07       Impact factor: 5.304

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.